Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-64.53 Million ≈ $-75.45 Million USD) by net assets (€6.39 Billion ≈ $7.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 2TZ total liabilities for a breakdown of total debt and financial obligations.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monalisa Group Co Ltd Class A
SHE:002918
|
0.075x |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
0.284x |
|
Xilong Chemical Co Ltd
SHE:002584
|
-0.008x |
|
Tamar Petroleum Ltd
TA:TMRP
|
0.237x |
|
IPH Ltd
AU:IPH
|
0.104x |
|
Hippo Holdings Inc
NYSE:HIPO
|
0.040x |
|
Xiamen Savings Environmental
SHE:300056
|
0.030x |
|
Investment AB Oresund
ST:ORES
|
0.006x |
Annual Cash Flow Conversion Efficiency for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Tianjin Zhong Xin Pharmaceutical Group C stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.10 Billion ≈ $8.30 Billion |
€461.07 Million ≈ $539.03 Million |
0.065x | -44.87% |
| 2024-12-31 | €7.85 Billion ≈ $9.18 Billion |
€924.67 Million ≈ $1.08 Billion |
0.118x | +13.69% |
| 2023-12-31 | €6.65 Billion ≈ $7.77 Billion |
€688.49 Million ≈ $804.91 Million |
0.104x | +0.23% |
| 2022-12-31 | €6.55 Billion ≈ $7.66 Billion |
€677.25 Million ≈ $791.77 Million |
0.103x | -21.01% |
| 2021-12-31 | €6.51 Billion ≈ $7.62 Billion |
€852.40 Million ≈ $996.55 Million |
0.131x | +15.96% |
| 2020-12-31 | €5.95 Billion ≈ $6.96 Billion |
€671.42 Million ≈ $784.96 Million |
0.113x | +25.79% |
| 2019-12-31 | €5.52 Billion ≈ $6.46 Billion |
€495.49 Million ≈ $579.28 Million |
0.090x | +29.50% |
| 2018-12-31 | €5.05 Billion ≈ $5.91 Billion |
€350.14 Million ≈ $409.36 Million |
0.069x | +8165.98% |
| 2017-12-31 | €4.63 Billion ≈ $5.41 Billion |
€-3.97 Million ≈ $-4.64 Million |
-0.001x | -100.88% |
| 2016-12-31 | €4.30 Billion ≈ $5.03 Billion |
€417.77 Million ≈ $488.42 Million |
0.097x | +10.55% |
| 2015-12-31 | €4.11 Billion ≈ $4.80 Billion |
€360.58 Million ≈ $421.56 Million |
0.088x | -9.77% |
| 2014-12-31 | €2.95 Billion ≈ $3.44 Billion |
€286.85 Million ≈ $335.36 Million |
0.097x | +17.45% |
| 2013-12-31 | €2.57 Billion ≈ $3.01 Billion |
€213.44 Million ≈ $249.53 Million |
0.083x | -- |
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more